Related references
Note: Only part of the references are listed.A panoramic review of IL-6: Structure, pathophysiological roles and inhibitors
Sukhvir Kaur et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2020)
Ingested ACTH blocks Th17 production by inhibiting GALT IL-6
Landon J. Dittel et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2020)
Lipopolysaccharide enhances human herpesvirus 1 replication and IL-6 release in epithelial cells
Weiting Zeng et al.
MICROBIAL PATHOGENESIS (2020)
Molecular and functional characterization of IL-6 receptor (IL-6R) and glycoprotein 130 (gp130) in Nile tilapia (Oreochromis niloticus)
Enxu Zhou et al.
DEVELOPMENTAL AND COMPARATIVE IMMUNOLOGY (2020)
Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies
Ming Zhao
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality
Chi Zhang et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
A new threat from an old enemy: Re-emergence of coronavirus (Review)
Anca Oana Docea et al.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2020)
Towards effective COVID-19 vaccines: Updates, perspectives and challenges (Review)
Daniela Calina et al.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2020)
Saliva is a reliable tool to detect SARS-CoV-2
Lorenzo Azzi et al.
JOURNAL OF INFECTION (2020)
Tocilizumab treatment in COVID-19: A single center experience
Pan Luo et al.
JOURNAL OF MEDICAL VIROLOGY (2020)
Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?
Bingwen Liu et al.
JOURNAL OF AUTOIMMUNITY (2020)
Hypoxia regulates angeogenic-osteogenic coupling process via up-regulating IL-6 and IL-8 in human osteoblastic cells through hypoxia-inducible factor 1 alpha pathway
Xiulong Niu et al.
CYTOKINE (2019)
Rosacea-like demodicosis (but not primary demodicosis) and papulopustular rosacea may be two phenotypes of the same disease - a microbioma, therapeutic and diagnostic tools perspective
A. L. Tatu et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2019)
Caffeine-stimulated muscle IL-6 mediates alleviation of non-alcoholic fatty liver disease
Chongye Fang et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2019)
Therapeutic blockade of the interleukin-6 receptor (IL-6R) allows sIL-6R generation by proteolytic cleavage
Niklas Prenissl et al.
CYTOKINE (2019)
Influenza Vaccination Induces NK-Cell-Mediated Type-II IFN Response that Regulates Humoral Immunity in an IL-6-Dependent Manner
Yagmur Farsakoglu et al.
CELL REPORTS (2019)
Heterotypic cell-in-cell structures in colon cancer can be regulated by IL-6 and lead to tumor immune escape
Shan Wang et al.
EXPERIMENTAL CELL RESEARCH (2019)
Interleukin-6 (IL-6) mediates protection against glucose toxicity in human Muller cells via activation of VEGF-A signaling
Brandon A. Coughlin et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2019)
Structure-based design and synthesis of new 4-methylcoumarin-based lignans as pro-inflammatory cytokines (TNF-α, IL-6 and IL-1β) inhibitors
S. Santhosh Kumar et al.
BIOORGANIC CHEMISTRY (2019)
Imiquimod and interferon-alpha augment monocyte-mediated astrocyte secretion of MCP-1, IL-6 and IP-10 in a human co-culture system
Michael D. Rizzo et al.
JOURNAL OF NEUROIMMUNOLOGY (2019)
Il-6 Involvement in pain, fatigue and mood disorders in rheumatoid arthritis and the effects of Il-6 inhibitor sarilumab
Fabiola Atzeni et al.
PHARMACOLOGICAL RESEARCH (2019)
Plasma interleukin 6 levels are associated with cardiac function after ST-elevation myocardial infarction
Hilde E. Groot et al.
CLINICAL RESEARCH IN CARDIOLOGY (2019)
Inhibition of interleukin-6 trans-signaling prevents inflammation and endothelial barrier disruption in retinal endothelial cells
Maria L. Valle et al.
EXPERIMENTAL EYE RESEARCH (2019)
New insights in vitiligo treatments using bioactive compounds from Piper nigrum
Bianca Mihaila et al.
EXPERIMENTAL AND THERAPEUTIC MEDICINE (2019)
Exercise and health - emerging roles of IL-6
Helga Ellingsgaard et al.
CURRENT OPINION IN PHYSIOLOGY (2019)
Endothelial Robo4 regulates IL-6 production by endothelial cells and monocytes via a crosstalk mechanism in inflammation
Keisuke Shirakura et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2018)
Rethinking IL-6 and CRP: Why they are more than inflammatory biomarkers, and why it matters
Marco Del Giudice et al.
BRAIN BEHAVIOR AND IMMUNITY (2018)
MUC16 C terminal-induced secretion of tumor-derived IL-6 contributes to tumor-associated Treg enrichment in pancreatic cancer
Kun Fan et al.
CANCER LETTERS (2018)
Interleukin-6 Delays Gastric Emptying in Humans with Direct Effects on Glycemic Control
Louise Lang Lehrskov et al.
CELL METABOLISM (2018)
IL-6 family cytokines: Key inflammatory mediators as biomarkers and potential therapeutic targets
Nese Unver et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2018)
Hypoxia-induced HMGB1 expression of HCC promotes tumor invasiveness and metastasis via regulating macrophage-derived IL-6
Jiang Jiang et al.
EXPERIMENTAL CELL RESEARCH (2018)
IL-6 deficiency alters spatial memory in 4-and 24-month-old mice
Izabela Bialuk et al.
NEUROBIOLOGY OF LEARNING AND MEMORY (2018)
Skeletal muscle secretion of IL-6 is muscle type specific: Ex vivo evidence
Ashley Paula Liang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2018)
PMA treated THP-1-derived-IL-6 promotes EMT of SW48 through STAT3/ERK-dependent activation of Wnt/beta-catenin signaling pathway
Sikang Gao et al.
BIOMEDICINE & PHARMACOTHERAPY (2018)
IL-6 is required for protective immune responses against early filarial infection
Muhsin Muhsin et al.
INTERNATIONAL JOURNAL FOR PARASITOLOGY (2018)
Real-time monitoring of IL-6 and IL-10 reporter expression for anti-inflammation activity in live RAW 264.7 cells
Papawee Saiki et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2018)
Significant association of IL-6-572G/C, IL-6-597G/A, and IL-6-174G/C polymorphisms and susceptibility to lumbar degenerative disease: A meta-analysis
Shu-tao Gao et al.
CLINICAL NEUROLOGY AND NEUROSURGERY (2018)
Underlying Causes and Therapeutic Targeting of the Inflammatory Tumor Microenvironment
Elizabeth A. Comen et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2018)
Contact Allergy to Topical Mometasone Furoate Confirmed by Rechallenge and Patch Test
Alin L. Tatu et al.
AMERICAN JOURNAL OF THERAPEUTICS (2018)
Polymorphisms of the IL-6, IL-8 and IL-10 genes and the risk of gastric pathology in patients infected with Helicobacter pylori
Ivy Bastos Ramis et al.
JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION (2017)
IL-6-mediated signaling pathways limit Chlamydia muridarum infection and exacerbate its pathogenicity in the mouse genital tract
Xin Sun et al.
MICROBES AND INFECTION (2017)
Interleukin 6 Inhibition and Coronary Artery Disease in a High-Risk Population: A Prospective Community-Based Clinical Study
Bruno Cesar Bacchiega et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2017)
Targeting inflammation to reduce cardiovascular disease risk: a realistic clinical prospect?
Paul Welsh et al.
BRITISH JOURNAL OF PHARMACOLOGY (2017)
Identifying the association between interleukin-6 and lichen planus: A meta-analysis
Meng Yin et al.
BIOMEDICAL REPORTS (2017)
IL-6 trans-signaling is another pathway to upregulate Osteopontin
Takaaki Uchibori et al.
CYTOKINE (2017)
Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis
Cem Gabay et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
EFFECT OF TOCILIZUMAB TREATMENT ON QTC INTERVAL IN PATIENTS WITH RHEUMATOID ARTHRITIS WITHOUT CARDIAC SYMPTOMS
I. Yokoe et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Revisiting IL-6 antagonism in multiple myeloma
Thomas Matthes et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
Inflammatory cytokines in atherosclerosis: current therapeutic approaches
Dimitris Tousoulis et al.
EUROPEAN HEART JOURNAL (2016)
Serum levels of HGF, IL-6, and TGF-α after benign liver tumor resection
Oskar Kornasiewicz et al.
ADVANCES IN MEDICAL SCIENCES (2015)
The varying faces of IL-6: From cardiac protection to cardiac failure
Jillian A. Fontes et al.
CYTOKINE (2015)
Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial
Tom W. J. Huizinga et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
IL-6 targeting compared to TNF targeting in rheumatoid arthritis: studies of olokizumab, sarilumab and sirukumab
Yoshiya Tanaka et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Inflammation and Atherosclerosis: A Review of the Role of Interleukin-6 in the Development of Atherosclerosis and the Potential for Targeted Drug Therapy
Joshua Hartman et al.
CARDIOLOGY IN REVIEW (2014)
The inflammatory response in myocardial injury, repair, and remodelling
Nikolaos G. Frangogiannis
NATURE REVIEWS CARDIOLOGY (2014)
The two faces of IL-6 in the tumor microenvironment
Daniel T. Fisher et al.
SEMINARS IN IMMUNOLOGY (2014)
Master regulator of intestinal disease: IL-6 in chronic inflammation and cancer development
Maximilian J. Waldner et al.
SEMINARS IN IMMUNOLOGY (2014)
High-Sensitivity C-Reactive Protein and Interleukin-6-Dominant Inflammation and Ischemic Stroke Risk The Northern Manhattan Study
Jorge M. Luna et al.
STROKE (2014)
Safety and Pharmacokinetics of Olokizumab, an Anti-IL-6 Monoclonal Antibody, Administered to Healthy Male Volunteers: A Randomized Phase I Study
Kosmas Kretsos et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2014)
The expression of IL-6 and STAT3 might predict progression and unfavorable prognosis in Wilms' tumor
Li-Juan Zhang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2013)
Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial
Cem Gabay et al.
LANCET (2013)
Cytokines and Chemokines in Irritant Contact Dermatitis
Haur Yueh Lee et al.
MEDIATORS OF INFLAMMATION (2013)
Inflammation in Atherosclerosis
Peter Libby
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2012)
IL-6 Muscles In on the Gut and Pancreas to Enhance Insulin Secretion
Tamara L. Allen et al.
CELL METABOLISM (2012)
The interleukin 6 pathway and atherosclerosis
Juergen Scheller et al.
LANCET (2012)
Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies
Nadeem Sarwar et al.
LANCET (2012)
The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis
Daniel I. Swerdlow et al.
LANCET (2012)
Interleukin-6 in oral diseases: a review
L. Nibali et al.
ORAL DISEASES (2012)
Association between Serum Interleukin-6 Concentrations and Mortality in Older Adults: The Rancho Bernardo Study
Jeffrey K. Lee et al.
PLOS ONE (2012)
Serum concentration of IL-6, IL-2, TNF-α, and IFNγ in Vitiligo patients
Suman Singh et al.
INDIAN JOURNAL OF DERMATOLOGY (2012)
Systemic inflammation (Interleukin 6) predicts all-cause mortality in men: results from a 9-year follow-up of the MEMO Study
Bernhard T. Baune et al.
AGE (2011)
The pro- and anti-inflammatory properties of the cytokine interleukin-6
Juergen Scheller et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2011)
Interleukin-6, but Not Soluble Adhesion Molecules, Predicts a Subsequent Mortality from Cardiovascular Disease in Patients with Acute ST-Segment Elevation Myocardial Infarction
Zhen-Xing Fan et al.
CELL BIOCHEMISTRY AND BIOPHYSICS (2011)
Rosacea: the Cytokine and Chemokine Network
Peter Arne Gerber et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS (2011)
Gut and liver handling of interleukin-6 during liver resection in man
Simon A. W. G. Dello et al.
HPB (2011)
Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study
G. Jones et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
C-Reactive Protein, Interleukin 6, Fibrinogen and Risk of Sudden Death in European Middle-Aged Men: The PRIME Study
Jean-Philippe Empana et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2010)
IL-6-transfected tumor cells modulate the status of CD8+ and CD4+ T cells to control tumor growth
Chia-Ling Hsieh et al.
IMMUNOBIOLOGY (2010)
C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis
Stephen Kaptoge et al.
LANCET (2010)
IL-6 and Stat3 Are Required for Survival of Intestinal Epithelial Cells and Development of Colitis-Associated Cancer
Sergei Grivennikov et al.
CANCER CELL (2009)
The major inflammatory mediator interleukin-6 and obesity
Katalin Eder et al.
INFLAMMATION RESEARCH (2009)
Inflammatory biomarkers in coronary artery disease
Epaminondas Zakynthinos et al.
JOURNAL OF CARDIOLOGY (2009)
Biomarkers to predict recurrent cardiovascular disease: The heart and soul study
Michael G. Shlipak et al.
AMERICAN JOURNAL OF MEDICINE (2008)
Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial
Josef S. Smolen et al.
LANCET (2008)
Long-term interleukin-6 levels and subsequent risk of coronary heart disease: Two new prospective studies and a systematic review
John Danesh et al.
PLOS MEDICINE (2008)
Mechanisms linking obesity with cardiovascular disease
Luc F. Van Gaal et al.
NATURE (2006)
Interleukin-6 and the risk of future cardiovascular events in patients with angina pectoris and/or healed myocardial infarction
Enrique Z. Fisman et al.
AMERICAN JOURNAL OF CARDIOLOGY (2006)
Plasma interleukin-6 predicts cardiovascular mortality in hemodialysis patients
M Rao et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2005)
Orally administered IL-6 induces elevated intestinal GM-CSF gene expression and splenic CFU-GM
FM Rollwagen et al.
CYTOKINE (2004)
Interleukin-6 is a stronger predictor of total and cardiovascular mortality than C-reactive protein in haemodialysis patients
V Panichi et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2004)
C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease - The PRIME study
G Luc et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2003)
Effects of hydrochlorothiazide and furosemide diuretics on human bone marrow stromal osteoprogenitor cells
CH Kim et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2000)
Share Paper
